Expression and clinical significance of serum microRNA663 in nasopharyngeal carcinoma patients

doi:10.3760/cma.j.issn.1673422X.2018.08.003

Abstract

Abstract: ObjectiveTo investigate the expression level of serum microRNA663 (miR663) in nasopharyngeal carcinoma (NPC) patients and its relationships with clinicopathological features and prognosis. MethodsThe serums of 60 NPC patients (NPC group), 40 patients with nasopharyngeal chronic inflammation (nasopharyngitis group) and 30 healthy subjects (health control group) were collected from June 2014 to April 2017 in our hospital. The relative expression levels of serum miR663 were detected by quantitative real time polymerase chain reaction (qRTPCR). The relationships between the expression of miR663 and clinicopathological features were analyzed. The diagnostic value of serum miR663 in patients with NPC was analyzed by receiver operating characteristic (ROC) curve. According to the optimal cutoff value determined by the ROC curve, the patients were divided into miR663≥optimal cutoff value group and miR663<optimal cutoff value group, and prognosis analysis was performed for the two groups. ResultsThe relative expression levels of miR663 among NPC group (6.38±2.05), nasopharyngitis group (3.11±0.97) and health control group(1.74±0.75) were significantly different (F=107.722, P=0.001). Serum miR663 level in NPC group was significantly higher than that in nasopharyngitis group and healthy control group, with significant differences (both P＜0.001). The relative expression level of miR663 in nasopharyngitis group was significantly higher than that in health control group, with a significant difference (P＜0.001). The relative expression of serum miR663 in patients with NPC was not related to patient′s age, sex and differentiation (t=1.832, P=0.072; t=0.578, P=0.565; F=0.132, P=0.877). The relative expression of miR663 in stage ⅠⅡ (5.24±1.98) was significantly lower than that in stage ⅢⅣ (6.99±1.84) of NPC patients, with a significant difference (t=3.417, P＜0.001). The relative expression of serum miR663 in patients with lymph node metastasis (7.55±1.38) was significantly higher than that in patients without lymph node metastasis (4.62±1.60), with a significant difference (t=7.572, P=0.001). The analysis of the diagnostic value of serum miR663 in patients with NPC using the ROC curve showed that the area under the curve (AUC) of miR663 was 0.939. When the optimal cutoff value of miR663 was 3.190, the sensitivity was 80.0% and the specificity was 89.0%. The median survival time in miR663≥3.190 group (21.7 months) was significantly shorter than that in miR663＜3.190 group (33.4 months), with a significant difference (χ2=4.332, P=0.037). ConclusionThe relative expression level of serum miR663 in patients with NPC is increased, and the expression level of miR663 is related to lymph node metastasis and clinical stage. High expression of miR663 predicts poor clinical outcomes, and miR663 may be a potential predictor of prognosis in patients with NPC.

Key words: Nasopharyngeal neoplasms, Prognosis, MicroRNA663

LAI Shi-Jia, ZHAO De-An, SUN Yong-Ming. Expression and clinical significance of serum microRNA663 in nasopharyngeal carcinoma patients[J]. Journal of International Oncology, 2018, 45(8): 460-464.

References

［1］李丹, 王勇. 微创外科治疗联合药物对局限性鼻咽癌微小浸润灶的近远期疗效分析［J］. 实用肿瘤学杂志, 2017, 31(3): 234237. DOI: 10.11904/j.issn.10023070.2017.03.008. ［2］ Jian P, Li ZW, Fang TY, et al. Retinoic acid induces HL60 cell differentiation via the upregulation of miR663［J］. J Hematol Oncol, 2011, 4: 20. DOI: 10.1186/17568722420. ［3］ Ni CW, Qiu H, Jo H. MicroRNA663 upregulated by oscillatory shear stress plays a role in inflammatory response of endothelial cells［J］. Am J Physiol Heart Circ Physiol, 2011, 300(5): H17621769. DOI: 10.1152/ajpheart.00829.2010. ［4］ Yi C, Wang Q, Wang L, et al. MiR663, a microRNA targeting p21(WAF1/CIP1), promotes the proliferation and tumorigenesis of nasopharyngeal carcinoma［J］. Oncogene, 2012, 31(41): 44214433. DOI: 10.1038/onc.2011.629. ［5］ Petersson F. Nasopharyngeal carcinoma: a review［J］. Semin Diagn Pathol, 2015, 32(1): 5473. DOI: 10.1053/j.semdp.2015.02.021. ［6］ Varol N, Konac E, Gurocak OS, et al. The realm of microRNAs in cancers［J］. Mol Biol Rep, 2011, 38(2): 10791089. DOI: 10.1007/s1103301002050. ［7］ Jiao L, Deng Z, Xu C, et al. miR663 induces castrationresistant prostate cancer transformation and predicts clinical recurrence［J］. J Cell Physiol, 2014, 229(7): 834844. DOI: 10.1002/jcp.24510. ［8］ Huang Y, Liu J, Fan L, et al. miR663 overexpression induced by endoplasmic reticulum stress modulates hepatocellular carcinoma cell apoptosis via transforming growth factor beta 1［J］. Onco Targets Ther, 2016, 9: 16231633. DOI: 10.2147/OTT.S96902. ［9］章广玲, 李宏杰, 熊亚南, 等. miR663通过靶向TGFB1对肺癌细胞A549增殖的调控［J］. 肿瘤防治研究, 2012, 39(8): 931935. DOI: 10.3971/j.issn.10008578.2012.08.012. ［10］ Liang S, Zhang N, Deng Y, et al. Increased serum level of microRNA663 is correlated with poor prognosis of patients with nasopharyngeal carcinoma［J］. Dis Markers, 2016, 2016: 7648215. DOI: 10.1155/2016/7648215.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[4]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[5]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[6]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei. Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction [J]. Journal of International Oncology, 2024, 51(4): 193-197.
[7]	Wan Fang, Yang Gang, Li Rui, Wan Qijing. Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer [J]. Journal of International Oncology, 2024, 51(4): 204-209.
[8]	Yao Yixin, Shen Yulin. Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE [J]. Journal of International Oncology, 2024, 51(4): 217-222.
[9]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[10]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[11]	Peng Qin, Cai Yuting, Wang Wei. Advances on KPNA2 in liver cancer [J]. Journal of International Oncology, 2024, 51(3): 181-185.
[12]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.
[13]	Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104.
[14]	Huang Zhen, Chen Yongshun. Research progress of circulating tumor DNA in the diagnosis and treatment of hepatocellular carcinoma [J]. Journal of International Oncology, 2024, 51(1): 59-64.
[15]	Wang Xiao, Li Ying, Luo Yujie, Jin Shu. Study on the prognostic value of serological indicators for nasopharyngeal carcinoma based on nomogram model [J]. Journal of International Oncology, 2023, 50(8): 463-469.